
Glenmark Pharmaceuticals launches GLIPIQ (semaglutide) in India for managing Type 2 Diabetes, aiming to improve access to GLP-1 therapy.
Alok Malik says the launch focuses on affordability, with weekly treatment starting at ₹325.
More here: afaqs.com/news/brands/gl…
#HealthcareNews #DiabetesCare #PharmaIndustry #Glenmark #MedicalInnovation
English


